Lack of effect of the specific cholecystokinin receptor antagonist loxiglumide on cholecystokinin clearance from plasma in man.
Saline or loxiglumide (2.5 mg kg-1 in 10 min, followed by 5 mg kg-1 h-1 for 200 min) was administered intravenously in random order to six healthy subjects. After 60 min cholecystokinin (CCK-33) was infused (0.5 i.d.u. kg-1 h-1 for 1 h then 1.0 i.d.u. kg-1 h-1 for 1 h). Loxiglumide did not change basal levels of CCK and did not augment plasma CCK-immunoreactivity during CCK-33 infusion. After cessation of the CCK-infusion, plasma CCK concentrations decreased rapidly to basal values within 12 min, and the elimination half-life during loxiglumide infusion (4.8 +/- 0.8 min) was not significantly different from that during saline infusion (4.2 +/- 1.0 min). These results suggest that loxiglumide does not interfere with the distribution and metabolism of CCK.
Jebbink
M C
MC
Department of Gastroenterology and Hepatology, University Hospital, Leiden, The Netherlands.
Jansen
J B
JB
Masclee
A A
AA
Lamers
C B
CB
D000328:Adult; D002766:Cholecystokinin / Q000037:antagonists & inhibitors / Q000097:blood* / Q000493:pharmacokinetics; D005260:Female; D005973:Glutamine / Q000031:analogs & derivatives*; D006207:Half-Life; D006801:Humans; D008297:Male; D011377:Proglumide / Q000031:analogs & derivatives* / Q000494:pharmacology
D005973:Glutamine; C053737:loxiglumide; D002766:Cholecystokinin; D011377:Proglumide